| 以分子分型为基础的肺癌靶向治疗研究进展 |
| |
| 引用本文： | 蒋日成. 以分子分型为基础的肺癌靶向治疗研究进展[J]. 中国肿瘤临床, 2012, 39(2): 114-117. DOI: 10.3969/j.issn.1000-8179.2012.02.015 |
| |
| 作者姓名： | 蒋日成 |
| |
| 作者单位： | 天津医科大学附属肿瘤医院, 天津市肺癌诊治中心, 肺部肿瘤内科（天津市 300060） |
| |
| 基金项目： | 国家自然科学基金(编号:81000899);天津市科委科技计划基金(编号:11JCZDJC18900)资助 |
| |
| 摘 要： | 随着基因分析技术的不断发展, 对肿瘤的发病机制以及治疗的研究愈加透彻。依靠传统的组织病理学分类无法充分实现对肿瘤患者的个体化治疗方案选择在制定临床研究的方案时, 研究者在考虑病理类型和临床因素之外, 还要充分考虑受试个体的基因特征。那么, 分子异常改变对肿瘤治疗意义如何, 以基因特征为基础的肿瘤临床试验时代离我们到底有多远?本文在此将可能影响肿瘤治疗方向的基因改变类型, 以及近年肺癌研究领域一系列基于分子特征的临床试验做一综述。
|
| 关 键 词： | 非小细胞肺癌 分子分型 临床试验 靶向治疗 |
| 收稿时间： | 2011-12-12 |
Advances in the Research on Target Therapy for Lung Cancer Based on Molecular Profiling |
| |
| Richeng JIANG. Advances in the Research on Target Therapy for Lung Cancer Based on Molecular Profiling[J]. Chinese Journal of Clinical Oncology, 2012, 39(2): 114-117. DOI: 10.3969/j.issn.1000-8179.2012.02.015 |
| |
| Authors: | Richeng JIANG |
| |
| Affiliation: | Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China |
| |
| Abstract: | Considerable advances have evolved in the pathogenesis and therapy of malignant tumors with the development of the gene analysis technique. Traditional histo-pathological classification is inadequate for the selection of personalized treatment for cancer patients. Clinical trial investigators have to consider not only the tumor pathologic type and clinical factors, but also the genetic characteristics of the patients. Therefore, the types of molecular alterations needs to be investigated and the period of molecular profiling should be determined. In the present paper the non-small cell lung cancer-related molecular alterations and critical clinic trials based on these molecular events were reviewed. |
| |
| Keywords: | |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
